Genetic variation in the human cytochrome P450 supergene family

Pharmacogenetics and Genomics

Volumn 25, Issue 12, 2015, Pages 584-594

  Fujikura, Kohei ^a   Ingelman Sundberg, Magnus ^b   Lauschke, Volker M ^b  

^a KOBE UNIVERSITY HOSPITAL   (Japan)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

cytochrome P450 enzyme system; gene frequency; genetic polymorphism; genetic variation

Indexed keywords

AFRICAN AMERICAN; ARTICLE; CYTOCHROME P450 GENE; ETHNIC DIFFERENCE; ETHNIC GROUP; EUROPEAN AMERICAN; GENE; GENE FREQUENCY; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC CODE; GENETIC VARIABILITY; HUMAN; HUMAN GENOME; MULTIGENE FAMILY; POPULATION SIZE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; CAUCASIAN; GENETICS; MULTIVARIATE ANALYSIS;

CYTOCHROME P450;

AFRICAN AMERICANS; CYTOCHROME P-450 ENZYME SYSTEM; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENOME, HUMAN; HUMANS; MULTIVARIATE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84946707237     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000172     Document Type: Article

References (46)

1. Nelson MR, Wegmann D, Ehm MG, Kessner D, St Jean P, Verzilli C, et al. An abundance of rare functional variants in 202 drug target genes sequenced in 14 002 people 002 people. Science 2012; 337:100-104.
2. Sim SC, Ingelman-Sundberg M. The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects. Hum Genomics 2010; 4:278-281.
3. Nebert DW, Dalton TP. The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer 2006; 6:947-960.
4. Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet 2002; 360:1155-1162.
5. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348:529-537.
6. Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA. Applications of CYP450 testing in the clinical setting. Mol Diagn Ther 2013; 17:165-184.
7. Harper AR, Topol EJ. Pharmacogenomics in clinical practice and drug development. Nat Biotechnol 2012; 30:1117-1124.
8. Shahin MH, Johnson JA. Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice? Curr Opin Cardiol 2013; 28:305-314.
9. Spina E, de Leon J. Clinical applications of CYP genotyping in psychiatry. J Neural Transm 2015; 122:5-28.
10. Attard G, Reid AHM, A'Hern R, Parker C, Oommen NB, Folkerd E, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 27:3742-3748.
11. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003; 348:2431-2442.
12. Colomer R, Monzo M, Tusquets I, Rifa J, Baena JM, Barnadas A, et al. A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma. Clin Cancer Res 2008; 14:811-816.
13. Fontein DB, Houtsma D, Nortier JW, Baak-Pablo RF, Kranenbarg EM, van der Straaten TR, et al. Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial. Breast Cancer Res Treat 2014; 144:599-606.
14. McFadyen MC, Melvin WT, Murray GI. Cytochrome P450 enzymes: novel options for cancer therapeutics. Mol Cancer Ther 2004; 3:363-371.
15. Travica S, Pors K, Loadman PM, Shnyder SD, Johansson I, Alandas MN, et al. Colon cancer-specific cytochrome P450 2W1 converts duocarmycin analogues into potent tumor cytotoxins. Clin Cancer Res 2013; 19:2952-2961.
16. Gordon AS, Tabor HK, Johnson AD, Snively BM, Assimes TL, Auer PL, et al. NHLBI GO Exome Sequencing Project. Quantifying rare, deleterious variation in 12 human cytochrome P450 drug-metabolism genes in a largescale exome dataset. Hum Mol Genet 2014; 23:1957-1963.
17. Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP); Seattle, WA. Available at: http://evs. gs. washington. edu/EVS/. [Accessed May 2015]
18. Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, et al. 1000 Genomes Project Consortium. An integrated map of genetic variation from 1092 human genomes. Nature 2012; 491:56-65.
19. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010; 7:248-249.
20. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding nonsynonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009; 4:1073-1081.
21. Gravel S. Population genetics models of local ancestry. Genetics 2012; 191:607-619.
22. Drögemöller BI, Wright GE, Niehaus DJ, Emsley R, Warnich L. Nextgeneration sequencing of pharmacogenes: a critical analysis focusing on schizophrenia treatment. Pharmacogenet Genomics 2013; 23: 666-674.
23. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, Goldstein JA. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001; 11:597-607.
24. Gao Y, Liu D, Wang H, Zhu J, Chen C. Functional characterization of five CYP2C8 variants and prediction of CYP2C8 genotype-dependent effects on in vitro and in vivo drug-drug interactions. Xenobiotica 2010; 40:467-475.
25. Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, et al. CYP4F2 genetic variant alters required warfarin dose. Blood 2008; 111:4106-4112.
26. Cooper GM, Stone EA, Asimenos G, Green ED, Batzoglou S, Sidow A. NISC Comparative Sequencing Program. Distribution and intensity of constraint in mammalian genomic sequence. Genome Res 2005; 15:901-913.
27. Grantham R. Amino acid difference formula to help explain protein evolution. Science 1974; 185:862-864.
28. Masimirembwa CM, Otter C, Berg M, Jönsson M, Leidvik B, Jonsson E, et al. Heterologous expression and kinetic characterization of human cytochromes P-450: validation of a pharmaceutical tool for drug metabolism research. Drug Metab Dispos 1999; 27:1117-1122.
29. Tennessen JA, Bigham AW, O'Connor TD, Fu W, Kenny EE, Gravel S, et al. Broad GO; Seattle GO; NHLBI Exome Sequencing Project. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science 2012; 337:64-69.
30. Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin RM, Gibbs RA, et al. 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. Nature 2010; 467:1061-1073.
31. Sim SC, Ingelman-Sundberg M. Pharmacogenomic biomarkers: new tools in current and future drug therapy. Trends Pharmacol Sci 2011; 32:72-81.
32. Mornet E, Dupont J, Vitek A, White PC. Characterization of two genes encoding human steroid 11 beta-hydroxylase (P-450(11) beta). J Biol Chem 1989; 264:20961-20967.
33. Hashizume T, Imaoka S, Mise M, Terauchi Y, Fujii T, Miyazaki H, et al. Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J Pharmacol Exp Ther 2002; 300:298-304.
34. Mast N, White MA, Bjorkhem I, Johnson EF, Stout CD, Pikuleva IA. Crystal structures of substrate-bound and substrate-free cytochrome P450 46A1, the principal cholesterol hydroxylase in the brain. Proc Natl Acad Sci USA 2008; 105:9546-9551.
35. Chuang SS, Helvig C, Taimi M, Ramshaw HA, Collop AH, Amad M, et al. CYP2U1, a novel human thymus-and brain-specific cytochrome P450, catalyzes omega-and (omega-1)-hydroxylation of fatty acids. J Biol Chem 2004; 279:6305-6314.
36. Frueh FW, Amur S, Mummaneni P, Epstein RS, Aubert RE, DeLuca TM, et al. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use. Pharmacotherapy 2008; 28:992-998.
37. Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 2011; 90:625-629.
38. Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, et al. Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther 2013; 94:317-323.
39. Crews KR, Gaedigk A, Dunnenberger HM, Klein TE, Shen DD, Callaghan JT, et al. Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther 2012; 91:321-326.
40. Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE, et al. Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther 2014; 95:376-382.
41. Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee W, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther 2015; 98:19-24.
42. Pirooznia M, Kramer M, Parla J, Goes FS, Potash JB, McCombie WR, Zandi PP. Validation and assessment of variant calling pipelines for nextgeneration sequencing. Hum Genomics 2014; 8:14.
43. Shigemizu D, Fujimoto A, Akiyama S, Abe T, Nakano K, Boroevich KA, et al. A practical method to detect SNVs and indels from whole genome and exome sequencing data. Sci Rep 2013; 3:2161.
44. Linderman MD, Brandt T, Edelmann L, Jabado O, Kasai Y, Kornreich R, et al. Analytical validation of whole exome and whole genome sequencing for clinical applications. BMC Med Genomics 2014; 7:20.
45. Wetterstrand KA. DNA sequencing costs: data from the NHGRI Genome Sequencing Program (GSP). Available at: http://www. genome. gov/ sequencingcosts. [Accessed 21 August 2015]
46. Rasmussen-Torvik LJ, Stallings SC, Gordon AS, Almoguera B, Basford MA, Bielinski SJ, et al. Design and anticipated outcomes of the eMERGE-PGx project: a multicenter pilot for preemptive pharmacogenomics in electronic health record systems. Clin Pharmacol Ther 2014; 96:482-489.